Ligand saves $15M CVR as it licenses DARA to Retrophin
This article was originally published in Scrip
Executive Summary
Ligand Pharmaceuticals has licensed the rights to DARA (a dual acting receptor antagonist of angiotensin and endothelin receptors) to Retrophin and because the deal was completed after year-end 2011, Ligand has saved itself some $15 million. Ligand acquired DARA when it bought Pharmacopeia in 2008. The timing of the recent deal means that Ligand does not have to pay Pharmacopeia's former stockholders a payout for contingent value rights (CVRs) linked to DARA which were a part of the original acquisition deal.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.